FDA puts the brakes on a rare disease biotech’s PhIII as regulators wait for an update — shares crumble
Little Abeona Therapeutics $ABEO is back in trouble this morning.
The biotech reported that the FDA is slamming the brakes on their Phase III study …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
